palbociclib

all catalysts(0)

nothing on the calendar yet

News(7)

• Pfizer expands multibillion-dollar cost-cutting plan
  Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
  biopharma_dive · 16d ago
• Celcuity gains FDA approval for closely watched breast cancer drug
  Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
  biopharma_dive · 1mo ago
• Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
  Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
  biopharma_dive · 2mo ago
• RallyBio tries again for reverse merger, this time with Avenzo
  It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
  biopharma_dive · 2mo ago
• The OncFive: Top Oncology Articles for the Week of 5/3
  The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.
  onclive · 3mo ago
• Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
  Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.
  onclive · 3mo ago
• ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
  Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
  onclive · 3mo ago